Based on: Prostate Cancer — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 55 candidate interventions for prostate Cancer that are either approved medicines or have at least one registered clinical trial, built on 11 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 9 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Abiraterone Acetate — 3 registered trials · approved medicine · NCT01637402 NCT07198633 NCT07406282
- Apalutamide — 3 registered trials · approved medicine · NCT03371719 NCT03767244 NCT07406282
- Degarelix — 3 registered trials · approved medicine · NCT00268892
- enzalutamide — 3 registered trials · approved medicine · NCT07198633 NCT07406282 NCT02407054
- Docetaxel — 3 registered trials · investigational · NCT00165399 NCT00004001 NCT00005096
- Radium-223 dichloride (Xofigo, BAY88-8223) — 3 registered trials · investigational · NCT01565746
- Darolutamide — 2 registered trials · approved medicine · NCT05762536 NCT07406282
- Estramustine — 2 registered trials · approved medicine · NCT00165399 NCT00004001
- prednisone — 2 registered trials · approved medicine · NCT00004001 NCT01637402
- 68Ga-PSMA-11 — 2 registered trials · investigational · NCT05670106 NCT02673151
- Biospecimen Collection — 2 registered trials · investigational · NCT07200830 NCT07164027
- Bone scan — 2 registered trials · investigational · NCT03493945 NCT07200830
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in prostate Cancer and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: AKT1, AR, BRCA1, BRCA2, CYP17A1, FOLH1, KLK3, PARP1, PTEN, SRD5A2, TMPRSS2.
Which trials are registered?
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737 · Recruiting · Phase PHASE3 · started 2025-05-13
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer NCT03678025 · Recruiting · Phase PHASE3 · started 2018-09-24
- Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer NCT05346848 · Recruiting · Phase PHASE2 · started 2023-02-24
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 · Recruiting · Phase PHASE2 · started 2019-05-13
- Study of Oral MRT-2359 With Apalutamide in Prostate Cancer NCT07745361 · Recruiting · Phase PHASE2 · started 2026-08-18
- Comparing Moderately and Ultra Hypofractionated Radiation Treatments for Post-operative Prostate Cancer NCT06409910 · Recruiting · Phase PHASE2 · started 2024-11-26
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis NCT01441089 · Recruiting · started 2012-05-21
- Agriculture Health Study NCT00352924 · Active Not Recruiting · started 1993-04-30
- Precision-Based Genomics in Prostate Cancer NCT04706663 · Recruiting · started 2021-09-14
- Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies NCT04541030 · Active Not Recruiting · started 2020-09-02
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.